BioAdaptives to Acquire Xycota; Founders Get 40% Economics and Eventual 51% Voting Control
BDPT has more than doubled off its 52-week low of $0.001 on light trading volume (0.2× avg).
Summary
BioAdaptives signed a definitive agreement to buy preclinical CNS biotech Xycota for no cash, paying with preferred stock worth 40% of the company and eventually 51% of voting control — a control transfer that heavily dilutes existing shareholders.
Key Events · M&A and Partnerships · BDPT
-
Definitive Xycota Acquisition Signed
A Membership Interest Purchase Agreement dated October 29, 2026 gives BioAdaptives 100% of Xycota Biosciences LLC, a preclinical CNS company with a sub-perceptual psilocybin PTSD candidate and an exosome psilocin FTD program. No cash purchase price is payable.
-
Founders Get 40% Economics, Then 51% Votes
The new Economic Preferred is sized to 40% of total voting power and economic ownership — about 261 million common-equivalent shares on the illustrative ~391.3 million Closing Snapshot Denominator. Separately, a non-convertible Voting Preferred issued to CEO James Keener carries 51% of votes and transfers to the founders on a Control Event or spin-off.
-
Only $150,000 of Cash, All to Xycota
Investors Monroe Street Capital Partners and Lambda Ventures fund $150,000 in four tranches ($40,000/$40,000/$40,000/$30,000) against 12-month convertible notes with a 10% original issue discount and 10% one-time interest charge. A further $400,000 is called only on a Control Event, $400,000 is optional, and up to $160,000 covers reporting and spin-off costs.
-
Series C Super-Voting Rights Neutralized
Keener's 1,000,000 Series C shares (1,000 votes each, 100-for-1 conversion) are voted one-vote-per-share under an irrevocable transfer-agent instruction. Of those, 200,000 shares are escrowed and cancelled unless the nutraceutical business books $100,000 of qualifying third-party revenue within 18 months of closing.
Analysis · BDPT · Life Sciences
Effective control of BioAdaptives is being handed to Xycota's two founders in exchange for a preclinical biotech with no clinical trial yet dosed and no approved product. On its own, the Economic Preferred equals roughly 261 million common-equivalent shares against an illustrative ~391.3 million share denominator — existing holders are diluted to a minority of both economics and votes. CEO James Keener's 51% Voting Preferred is pledged to transfer to the founders the moment Xycota hits a regulatory milestone (an FDA Orphan Drug grant or a Health Canada/REB authorization). The only cash coming in is $150,000 of tranched investor money earmarked for Xycota, not the parent, against convertible notes that convert into more stock. For a company that already disclosed going-concern doubt and heavy dilution from debt conversions in its August 10-Q, this is a survival-and-control transaction rather than a growth deal: the nutraceutical business is ring-fenced and slated for a possible spin-off, and the parent's legacy liabilities stay with the parent.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDPT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $334.8K. The 52-week trading range was $0.00 to $0.08. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.